Assessment of the state of the epidemiological situation of lymphogranulomatosis in different regions of Ukraine as an important component in the development of directions for improvement of pharmaceutical support of oncohematological patients

Authors

DOI:

https://doi.org/10.15587/2519-4852.2020.221043

Keywords:

epidemiology of lymphogranulomatosis, epidemiology of Hodgkin's disease, morbidity, lymphomas, Hodgkin's lymphoma, lymphogranulomatosis, oncohematology, oncoepidemiology, mortality, Hodgkin's disease

Abstract

The aim: to conduct epidemiological studies of the morbidity and mortality of the population from lymphogranulomatosis in the regions of the country in dynamics over the years and to identify regions of the country that require special attention in the process of early detection of this pathology and effective pharmaceutical provision of patients.

Materials and methods. The object of the research was the official data of the National Cancer Registry from 2012-2019. The research used both general theoretical (historical, analytical and comparative, systemic, graphic, logical, hypothetical-deductive) and applied (mathematical-statistical, epidemiological) methods of research.

Results. It has been established that the average morbidity and mortality rates of the population from lymphogranulomatosis in Ukraine exceed similar world data (morbidity/mortality – 2.3/0.4 for men and 1.9/0.3 for women per 100 thousand population). Thus, the calculated morbidity rates were 2.5, and the mortality rate was 0.7 per 100 thousand population. It has been proved that morbidity and mortality rates by region varied in a significant range of values, namely, morbidity – from 1.8 (Transcarpathian region) to 3.0 (Kyiv), and mortality – from 0.4 (Cherkasy region) to 0.9 (Ivano-Frankivsk, Kyiv, Chernivtsi regions) per 100 thousand population. According to the results of the grouping, most regions of the country (14 regions and Kyiv city) were assigned to the group of extremely unfavourable (group D) development of the epidemiological situation in terms of lymphogranulomatosis. Ivano-Frankivsk region was attributed to the group of unfavourable (group C) development of this process. Four (Transcarpathian, Vinnytsia, Zhytomyr and Kherson) regions were included in the group of favourable (group A) development of the epidemiological situation. The group of relatively favourable (group B) – three areas. These are the Volyn, Chernigov and Cherkasy regions.

Conclusions. The presence of an extremely unfavourable (14 regions and Kyiv city) and unfavourable (Ivano-Frankivsk region) onco-epidemiological situation necessitates the development and implementation of regional programs for the early detection of lymphogranulomatosis and the provision of patients with affordable and effective anticancer drugs in accordance with the existing resource provision at the level of regions and local communities

Author Biographies

Hanna Panfilova, National Pharmaceutical University Pushkinska str., 53, Kharkiv, Ukraine, 61002

Doctor of Pharmaceutical Sciences, Professor

Department of Organization and Economics of Pharmacy

Marta Matushchak, Higher State Educational Institution of Ukraine «Bukovinian State Medical University» Teatralna sq., 2, Chernivtsi, Ukraine, 58002

Assistant

Department of Pharmaceutical Botany and Pharmacognosy

Liliia Kostyshyn, Higher State Educational Institution of Ukraine «Bukovinian State Medical University» Teatralna sq., 2, Chernivtsi, Ukraine, 58002

Assistant

Department of Pharmaceutical Botany and Pharmacognosy

Olha Skrynchuk, Higher State Educational Institution of Ukraine «Bukovinian State Medical University» Teatralna sq., 2, Chernivtsi, Ukraine, 58002

Assistant

Department of Pharmacy

Zyro Dominik, Medical University of Lodz Pl. Hallera 1, 90-647, Lodz, Poland

Department of Bioinorganic Chemistry

Chair of Medicinal Chemistry

Oksana Tsurikova, National University of Pharmacy Pushkinska str., 53, Kharkiv, Ukraine, 61002

PhD, Assistant

Department of Мanagement, Еconomics and Quality Assurance in Pharmacy

References

  1. Khodamoradi, F., Pakzad, R., Ghoncheh, M., Gandomani, H. S., Salehiniya, H. (2018). Еpidemiology, incidence and mortality of Hodgkin’s cancer in the world and its relation with development. WCRJ, 5 (2), e1085.
  2. Torre, L. A., Bray, F., Siegel, R. L., Ferlay, J., Lortet-Tieulent, J., & Jemal, A. (2015). Global cancer statistics, 2012. CA: A Cancer Journal for Clinicians, 65 (2), 87–108. doi: http://doi.org/10.3322/caac.21262
  3. Marri, P. R., Ansell, S. M. (2013). Progress in the initial management of Hodgkin’s Lymphoma. Transfusion and Apheresis Science, 49 (1), 12–18. doi: http://doi.org/10.1016/j.transci.2013.05.018
  4. Lin, J., Siegartel, L. R., Lingohr-Smith, M., Menges, B., Makenbaeva, D. (2017). Using Health Care Claims Data to Assess the Prevalence of Hodgkin Lymphoma and Relapsed or Refractory Hodgkin Lymphoma in the United States. Clinical Therapeutics, 39 (2), 303–310. doi: http://doi.org/10.1016/j.clinthera.2016.12.010
  5. Gobbi, P. G., Ferreri, A. J. M., Ponzoni, M., Levis, A. (2013). Hodgkin lymphoma. Critical Reviews in Oncology/Hematology, 85 (2), 216–237. doi: http://doi.org/10.1016/j.critrevonc.2012.07.002
  6. Eyre, T. A., King, A. J., Collins, G. P. (2013). Classical Hodgkin's lymphoma: past, present and future perspectives. British Journal of Hospital Medicine, 74 (11), 612–618. doi: http://doi.org/10.12968/hmed.2013.74.11.612
  7. Vassilakopoulos, T. P., Angelopoulou, M. K. (2013). Advanced and Relapsed/Refractory Hodgkin Lymphoma: What Has Been Achieved During the Last 50 Years. Seminars in Hematology, 50 (1), 4–14. doi: http://doi.org/10.1053/j.seminhematol.2013.02.002
  8. Salati, M., Cesaretti, M., Macchia, M., El Mistiri, M., Federico, M. (2014). Epidemiological Overview of Hodgkin Lymphoma Across the Mediterranean Basin. Mediterranean Journal of Hematology and Infectious Diseases, 6 (1), e2014048. doi: http://doi.org/10.4084/mjhid.2014.048
  9. Khajedaluee, M., Dadgarmoghaddam, M., Saeedi, R., Izadi-Mood, Z., Abrishami, M., Zamani, M. (2014). Mortality, Morbidity, Survival, and Burden of Top 9 Cancers in a Developing Country. Razavi International Journal of Medicine, 2 (3). doi: http://doi.org/10.5812/rijm.20073
  10. Ansell, S. M. (2016). Hodgkin lymphoma: 2016 update on diagnosis, risk-stratification, and management. American Journal of Hematology, 91 (4), 434–442. doi: http://doi.org/10.1002/ajh.24272
  11. Siegel, R. L., Miller, K. D., Jemal, A. (2020). Cancer statistics, 2020. CA: A Cancer Journal for Clinicians, 70 (1), 7–30. doi: http://doi.org/10.3322/caac.21590
  12. Smith, E. C., Ziogas, A., Anton-Culver, H. (2012). Association between insurance and socioeconomic status and risk of advanced stage Hodgkin lymphoma in adolescents and young adults. Cancer, 118 (24), 6179–6187. doi: http://doi.org/10.1002/cncr.27684
  13. Sullivan, R., Kowalczyk, J. R., Agarwal, B., Ladenstein, R., Fitzgerald, E., Barr, R. et. al. (2013). New policies to address the global burden of childhood cancers. The Lancet Oncology, 14 (3), e125–e135. doi: http://doi.org/10.1016/s1470-2045(13)70007-x
  14. Houweling, T. A. J., Kunst, A. E. (2009). Socio-economic inequalities in childhood mortality in low- and middle-income countries: a review of the international evidence. British Medical Bulletin, 93 (1), 7–26. doi: http://doi.org/10.1093/bmb/ldp048
  15. Ansell, S. M. (2020). Hodgkin lymphoma: A 2020 update on diagnosis, risk‐stratification, and management. American Journal of Hematology, 95 (8), 978–989. doi: http://doi.org/10.1002/ajh.25856
  16. Macalalad, A. R., McAuliffe, M., Yang, H., Kageleiry, A., Zhong, Y., Wu, E. Q. et. al. (2015). The epidemiology and targeted therapies for relapsed and refractory CD30+ lymphomas. Current Medical Research and Opinion, 31 (3), 537–545. doi: http://doi.org/10.1185/03007995.2015.1008131
  17. Szabo, S. M., Hirji, I., Johnston, K. M., Juarez-Garcia, A., Connors, J. M. (2017). Treatment patterns and costs of care for patients with relapsed and refractory Hodgkin lymphoma treated with brentuximab vedotin in the United States: A retrospective cohort study. PLOS ONE, 12 (10), e0180261. doi: http://doi.org/10.1371/journal.pone.0180261
  18. Mahdavifar, N., Ghoncheh, M., Pakzad, R., Momenimovahed, Z., Salehiniya, H. (2016). Epidemiology, Incidence and Mortality of Bladder Cancer and their Relationship with the Development Index in the World. Asian Pacific Journal of Cancer Prevention, 17 (1), 381–386. doi: http://doi.org/10.7314/apjcp.2016.17.1.381
  19. Ferlay, J., Steliarova-Foucher, E., Lortet-Tieulent, J., Rosso, S., Coebergh, J. W. W., Comber, H. et. al. (2013). Cancer incidence and mortality patterns in Europe: Estimates for 40 countries in 2012. European Journal of Cancer, 49 (6), 1374–1403. doi: http://doi.org/10.1016/j.ejca.2012.12.027
  20. Abramson, J. S., Arnason, J. E., LaCasce, A. S., Redd, R., Barnes, J. A., Sokol, L. et. al. (2019). Brentuximab vedotin, doxorubicin, vinblastine, and dacarbazine for nonbulky limited-stage classical Hodgkin lymphoma. Blood, 134 (7), 606–613. doi: http://doi.org/10.1182/blood.2019001272
  21. Connors, J. M., Jurczak, W., Straus, D. J., Ansell, S. M., Kim, W. S., Gallamini, A. et. al. (2018). Brentuximab Vedotin with Chemotherapy for Stage III or IV Hodgkin’s Lymphoma. New England Journal of Medicine, 378 (4), 331–344. doi: http://doi.org/10.1056/nejmoa1708984
  22. Bröckelmann, P. J., Goergen, H., Keller, U., Meissner, J., Ordemann, R., Halbsguth, T. V. et. al. (2019). Nivolumab and AVD for Early-Stage Unfavorable Hodgkin Lymphoma (NIVAHL). Blood, 134 (1), 236. doi: http://doi.org/10.1182/blood-2019-122406
  23. Ramchandren, R., Domingo-Domènech, E., Rueda, A., Trněný, M., Feldman, T. A., Lee, H. J. et. al. (2019). Nivolumab for Newly Diagnosed Advanced-Stage Classic Hodgkin Lymphoma: Safety and Efficacy in the Phase II CheckMate 205 Study. Journal of Clinical Oncology, 37 (23), 1997–2007. doi: http://doi.org/10.1200/jco.19.00315
  24. De Angelis, R., Sant, M., Coleman, M. P., Francisci, S., Baili, P., Pierannunzio, D. et. al. (2014). Cancer survival in Europe 1999–2007 by country and age: results of EUROCARE-5 – a population-based study. The Lancet Oncology, 15 (1), 23–34. doi: http://doi.org/10.1016/s1470-2045(13)70546-1
  25. Tit, A., Martin-Moreno, J. M., Jelenc, M., Gorgojo, L., Harris, M. (Eds.) (2015). European Guide for Quality National Cancer Control Programme. National Institute of Public Health. Ljubljana, 113.
  26. National Cancer Registry of Ukraine: short description of the database as of January, 2020. Cancer in Ukraine 2018–2019. Available at: https://unci.org.ua/spetsialistam/nacionalnij-kancer-reyestr/
  27. Verkhovna Rada Ukrainy. Ofitsiinyi veb-portal. Administratyvno-terytorialnyi ustrii. Available at: http://static.rada.gov.ua/zakon/new/NEWSAIT/ADM/zmist.html
  28. Fang, J.-Q. (Ed.) (2017). Handbook of Medical Statistics. World Scientific, 850.
  29. Yasenchak, C. A., Tseng, W.-Y., Yap, M., Rembert, D., Patt, D. A. (2015). Economic impact of disease progression following front-line therapy in classical Hodgkin lymphoma. Leukemia & Lymphoma, 56 (11), 3143–3149. doi: http://doi.org/10.3109/10428194.2015.1030639
  30. National Comprehensive Cancer Network. NCCN Clinical Practice Guideline in Oncology (NCCN Guidelines): Hodgkin lymphoma (2013). Available at: https://www2.tri-kobe.org/nccn/guideline/hematologic/english/hodgkins.pdf
  31. Kushchevyi, Ye. V., Kriachok, I. A., Martynchyk, A. V., Filonenko, K. S. (2001). Likuvannia patsiientiv z retsydyvamy ta refrakternym perebihom limfomy Khodzhkina. Rol vysokodozovoi khimioterapii ta transplantatsii hemopoetychnykh stovburovykh klityn. Klinichna onkolohiia, 1 (1), 78–88.
  32. Sivkovych, S. O., Mnishenko, V. M., Kaliuta, A. O. (2014). Limfoma Khodzhkina: suchasni aspekty diahnostyky ta likuvannia. Zbirnyk naukovykh prats spivrobitnykiv NMAPO imeni P. L. Shupyka, 23 (3), 667–674.
  33. Eyre, T. A., King, A. J., Collins, G. P. (2013). Classical Hodgkin’s lymphoma: past, present and future perspectives. British Journal of Hospital Medicine, 74 (11), 612–618. doi: http://doi.org/10.12968/hmed.2013.74.11.612
  34. Krivets, D. Ia. (2001). Epidemiologiia limfogranulematoza v Ukraine v 1991–1998 gg. Onkologіia, 3 (1), 11–15.

Downloads

Published

2020-12-30

How to Cite

Panfilova, H., Matushchak, M., Kostyshyn, L., Skrynchuk, O., Dominik, Z., & Tsurikova, O. (2020). Assessment of the state of the epidemiological situation of lymphogranulomatosis in different regions of Ukraine as an important component in the development of directions for improvement of pharmaceutical support of oncohematological patients. ScienceRise: Pharmaceutical Science, (6 (28), 19–25. https://doi.org/10.15587/2519-4852.2020.221043

Issue

No. 6 (28) (2020)

Section

Pharmaceutical Science

License

Copyright (c) 2020 Hanna Panfilova, Marta Matushchak, Liliia Kostyshyn, Olha Skrynchuk, Zyro Dominik, Oksana Tsurikova

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Our journal abides by the Creative Commons CC BY copyright rights and permissions for open access journals.